The $900 billion U.S. coronavirus relief and government appropriations legislation (the Act) contains several important new drug price reporting and transparency measures, including certain provisions that were part of the Senate’s Prescription Drug Pricing Reduction Act of 2019 (S. 2543). Pharmaceutical manufacturers should take note of these new statutory provisions and monitor implementation. Learn more here.

See all Member News